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ABSTRACT
Dysregulated expression of translation initiation factors has been associated 
with carcinogenesis, but underlying mechanisms remains to be fully understood. 
Here we show that eIF4H (eukaryotic translation initiation factor 4H), an activator 
of the RNA helicase eIF4A, is overexpressed in lung carcinomas and predictive 
of response to chemotherapy. In lung cancer cells, depletion of eIF4H enhances 
sensitization to chemotherapy, decreases cell migration and inhibits tumor growth 
in vivo, in association with reduced translation of mRNA encoding cell-proliferation 
(c-Myc, cyclin D1) angiogenic (FGF-2) and anti-apoptotic factors (CIAP-1, BCL-xL). 
Conversely, each isoform of eIF4H acts as an oncogene in NIH3T3 cells by stimulating 
transformation, invasion, tumor growth and resistance to drug-induced apoptosis 
together with increased translation of IRES-containing or structured 5′UTR mRNAs. 
These results demonstrate that eIF4H plays a crucial role in translational control and 
can promote cellular transformation by preferentially regulating the translation of 
potent growth and survival factor mRNAs, indicating that eIF4H is a promising new 
molecular target for cancer therapy.
INTRODUCTION
One of the hallmarks of cancer cells is their ability 
to undergo rapid growth. This requires a sustained increase 
in protein synthesis and therefore cancer cell progression 
involves the dysregulation of translation, in particular that 
of specific transcripts that confer growth advantages [1, 2].
Translation initiation is dependent on the spatial 
and temporal interactions between many eIFs (eukaryotic 
translation Initiation Factors). First, a ribosome is recruited 
to the 5′ untranslated region (UTR) of the transcript. 
This involves the eIF4F complex which is composed of 
three initiation factors: the cap-binding protein eIF4E, 
the prototypical DEAD-box helicase eIF4A and the large 
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scaffold protein eIF4G that is able to directly interact with the 
eIF4E and eIF4A proteins (Figure 1A) [3–5]. Once the eIF4F 
complex has been recruited, eIF4A unwinds the inhibitory 
RNA secondary structure within the 5′UTR (Figure 1A), 
increasing the ability of the 40 S ribosomal subunit to bind to 
the mRNA. By itself, eIF4A displays a weak ATP-dependent 
helicase activity, but this is enhanced through a functional 
interaction with either eIF4H or eIF4B [6–12]. Neither eIF4B 
nor eIF4H exhibits a helicase activity in the absence of eIF4A 
but they promote the ATPase [7, 13–15], RNA-binding 
[7, 10, 12, 15, 16], and helicase activities [12–14, 17] of 
eIF4A. This allows eIF4A to efficiently unwind the secondary 
structures in the 5′UTR, to promote the efficient scanning of 
the ribosome up to the start codon. eIF4A-mediated RNA 
unwinding appears to be necessary for ribosome recruitment 
even for mRNA with few secondary structures [17]. Recently, 
it was demonstrated that the eIF4A/eIF4H complex can 
repetitively unwind RNA hairpins by transitioning eIF4A 
between an active and inactive conformation using energy 
from ATP hydrolysis. The complex can be inactivated using 
a specific inhibitor that is able to lock eIF4A in its inactive 
conformation [18].
As a translation initiation factor eIF4H plays an 
important role within the cell, yet it has not been well-
characterized compared to some of the other eIFs. eIF4H 
has two transcript variants as a result of alternative 
splicing, leading to the expression of two protein isoforms 
of 25 and 27 kDa. These share significant sequence 
homology with eIF4B. The function of eIF4B depends 
on its phosphorylation (on Ser422) by the ribosomal 
S6 kinase through a Rapamycin-sensitive pathway and 
several studies have shown the importance of eIF4B 
Ser422 phosphorylation for the initiation of cap-dependent 
translation [19, 20–22]. Interestingly, eIF4B and eIF4H 
hold homologous RNA recognition motif (RRM) domains, 
however eIF4H lacks the carboxy-terminal region 
containing the phosphorylation site, suggesting that eIF4H 
may be constitutively active. The eIF4H gene is located 
within the Williams-Beuren Syndrome critical genomic 
region. This pathology is an autosomal dominant disorder 
that results from a hemizygous deletion of sequences on 
chromosome 7q11.23, including the eIF4H gene region. The 
clinical outcome of this syndrome includes cardiovascular, 
renal, dysmorphologic and ophthalmic abnormalities as well 
as neurological and cognitive disorders. eIF4H-deficient 
knockout mouse harbors growth defects, body weight loss, 
brain abnormalities, altered neuronal morphology and 
several behavior anomalies. This demonstrates that eIF4H 
depletion may contribute to certain deficiencies associated 
with Williams-Beuren Syndrome [23].
Recent studies have implicated eIFs in the 
progression of various types of cancer. eIF4A was shown 
to be an oncogene in T-cell acute lymphoblastic leukaemia 
(T-ALL) where it is required for the translation of 
transcripts with 5′UTRs that can form G-quadruplexes [24]. 
In addition, eIF4B was reported to increase the synthesis 
of proteins associated with enhanced diffuse large B-cell 
lymphoma cell survival [25]. The 27 KDa eIF4H isoform 
was also found to be overexpressed in human colorectal 
and esophagus cancer tissues [26], where the silencing of 
only the long eIF4H isoform inhibited proliferation and 
induced apoptosis of colon cancer cells, suggesting that 
this isoform specifically contributes to cell proliferation 
and carcinogenesis. Nevertheless, the exact role of eIF4H 
in tumorigenesis and the molecular mechanisms involved 
are unknown. In this study, we have investigated the role of 
eIF4H in cellular transformation and its physiological role 
in mRNA translation both by overexpression of the two 
eIF4H isoforms in NIH3T3 cells and downregulation of the 
isoforms by RNA interference in lung cancer cells.
RESULTS
eIF4H isoform expression in lung tumors
We first investigated eIF4H expression in various tumor 
types using a high-density multiple organ tumor and normal 
tissue array, which contains 18 types of tumor alongside 
normal controls (MC5003, Biomax, US). Given that eIF4H 
was specifically highly expressed in many lung tumor tissue 
(Supplementary Figure S2A– S2D) but was undetectable or 
very low expressed in all normal lung tissue (Supplementary 
Figure S2E– S2G) we focus our study on lung tumors.
Alternative splicing of the eIF4H gene generates two 
transcript variants producing 25 kDa and 27 kDa protein 
products, thus we investigated their expression levels in 
lung tumors. For this purpose, total protein lysates were 
prepared from 12 matched samples of lung tumor (T) 
and adjacent normal tissue (N). We established that the 
expression levels of both eIF4H isoforms was significantly 
increased in lung carcinomas compared to corresponding 
healthy tissue (Figure 1B and Supplementary Figure S2H). 
The expression of eIF4A was also slightly increased in lung 
tumor patient samples, while there was no difference in the 
levels of eIF4B and PABP. eIF4H total protein expression in 
these tumors (Figure 1B, Supplementary Figure S2H) was 
confirmed by immunohistochemistry using histological 
sections of tumor (T) and adjacent normal tissue (N) (Figure 
1C and Supplementary Figure S2I).
We then performed eIF4H immunohistochemical 
detection on a small cell lung carcinoma tissue microarray 
(TMA; described in [27]). Positive eIF4H levels were 
associated with a lack of objective response (OR) in patients 
that received etoposide and cisplatin doublet chemotherapy. 
Indeed, in the patient group with no OR to treatment based 
on Response Evaluation Criteria in Solid Tumors (RECIST) 
criteria, only 20% of samples did not express eIF4H, while 
58.1% of patients in the group with OR showed no eIF4H 
staining (Figure 1D). These findings indicate that eIF4H 
expression may serve as a new molecular marker for 
predicting the response to etoposide and cisplatin therapy. 
No significant correlation between the expression of eIF4H 
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and overall survival was found probably due to the lack of 
statistical power of this small cohort.
Effect of eIF4H knockdown on drug-induced 
apoptosis and tumor progression
We evaluated the consequences of shRNA-mediated 
eIF4H depletion in A549 cells (lung carcinoma) and HeLa 
cells (cervical adenocarcinoma), by measuring drug-
induced apoptosis, cell proliferation, migration and tumor 
growth. eIF4H knockdown (eIF4H-kd) was validated by 
western blotting, and two independent clones exhibiting 
a high silencing efficiency were selected for these studies 
(Figure 2A and Supplementary Figure S3A).
Given that eIF4H was highly expressed in lung 
carcinomas displaying resistance to chemotherapy, we 
Figure 1: eIF4H expression in lung carcinomas. A. Schematic model for cap-dependent initiation. eIF4E interacts with the mRNA 
5′ cap structure and forms the eIF4F complex by association with the RNA helicase eIF4A and the scaffolding protein eIF4G. The helicase 
activity of eIF4A is stimulated by eIF4H or eIF4B (right-hand side). B. Western blot analysis of protein lysates prepared from 4 matched 
samples of lung carcinoma tumors (T) and adjacent non-tumoral tissues (N) Equal amounts of protein from each pair were resolved on 
SDS PAGE and immunoblotted with anti-eIF4A, eIF4B, PABP, eIF4H and β-actin (loading control) antibodies. C. eIF4H immunostaining 
of normal (N) and tumoral (T) tissues corresponding to samples 1 and 4 in (B). D. Objective Response (OR) to etoposide and cisplatin 
treatment based on the Response Evaluation Criteria in Solid Tumors (RECIST) of 53 patients with small cell lung carcinomas.
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Figure 2: In vitro and in vivo characterization of the effect of eIF4H knockdown in A549 cells. A. Expression analysis 
of eIF4H and β-actin (loading control) in either A549 wild type (WT) cells or stable clones expressing scrambled shRNA (sh SCR) or 
eIF4H-targeting shRNA (sh1-4H and sh2-4H). B. Caspase 3/7 activity induction after 8 hours treatment with etoposide (25 μM) or cisplatin 
(50 μM) in A549 cells expressing eIF4H (sh1 and sh2) or scrambled shRNA. C. PARP cleavage analysis by immunoblotting. A549 cells 
expressing eIF4H (sh1 and sh2) or scrambled shRNA were untreated or treated for 8 hours with etoposide (25 μM) or cisplatin (50 μM). Full 
length and typical PARP cleavage were detected. β-actin was used as a loading control. D. Cell proliferation of A549 cells stably expressing 
or scrambled shRNA under low serum conditions (0.5%) over 7 days using MTT. E. and F. Cell cycle analysis of A549 cells expressing 
eIF4H sh1 (E) or eIF4H sh2 (F) and scrambled shRNA was carried out using flow cytometry. G. Migration of A549 cells transfected with 
scrambled shRNA or eIF4H-targeting shRNA was measured in a Boyden chamber assay. Fold induction represent the average number of 
cells/field in the sh4H-expressing cells over control cells (Scr). H. Tumor volumes measured at indicated time points after subcutaneous 
injection of eIF4H-deficient or control A549 cells into 10 nude mice in each group. Error bars show SEM.
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first assessed the effect of eIF4H depletion on cisplatin 
or etoposide chemoresistance in vitro in A549 cells. As 
shown in Figure 2B, after 8 hours of cisplatin or etoposide 
treatment, eIF4H-kd cells displayed increased caspase 
3/7 activity compared to control shRNA-transfected cells. 
Similar results were obtained for HeLa cells treated with 
cisplatin (Supplementary Figure S3B). We also tested an 
alternative apoptotic response pathway by using western 
blotting to examine poly(ADP-ribose) polymerase (PARP) 
cleavage. Compared to control cells, eIF4H knockdown 
resulted in increased PARP cleavage in A549 cells treated 
with cisplatin or etoposide (Figure 2C). We next investigated 
the effect of eIF4H depletion on cell proliferation and cell 
cycle progression. Upon eIF4H silencing, cell proliferation 
in vitro under low serum conditions (Figure 2D) was 
significantly reduced. Similar results were obtained with 
HeLa cells (Supplementary Figure S3C). eIF4H silenced 
cells showed a reduction in the percentage of cells in 
G2/M and accumulation of cells in G1 phase (respectively 
82% and 82,7% versus 68,1% in control cells) indicating 
that eIF4H facilitates cell proliferation under low serum 
conditions (Figure 2E and 2F). Upon eIF4H silencing, cell 
migration (Figure 2G) was also significantly reduced.
Finally, the consequence of eIF4H depletion on lung 
tumor growth was assessed in a subcutaneous xenograft 
model. As shown in Figure 2H, eIF4H knockdown 
significantly inhibited A549 cell tumor growth compared 
with control groups (P < 0.001 at day 35). Similar results 
were obtained with HeLa cells (Supplementary Figure S3D).
Interestingly, upon immunofluorescence staining 
with CD31, we observed that angiogenesis was highly 
affected in engrafted A549 eIF4H knockdown cells 
compare to control A549 control cells (Supplementary 
Figure S4). Notably, density of CD31-positive vessels 
as well as pericyte coverage (α-SMA1+) was higher in 
control compare to eIF4H knockdown tumors.
Taken together, these data indicate that eIF4H 
expression not only enhances the resistance of tumoral 
cells to chemotherapeutic drugs but also promotes tumor 
growth and angiogenesis in nude mice.
Effect of eIF4H isoforms on NIH3T3 cell 
proliferation, transformation, invasion properties, 
and resistance to drug-induced apoptosis
In order to study the individual contributions of 
each eIF4H splice variant on malignant transformation, 
we generated NIH3T3 cell lines stably-expressing either 
the longer 27 kDa isoform (4HL) or the shorter 25 kDa 
isoform (4Hs) under the control of the CMV promoter. 
After selection and screening for eIF4H expression by 
western blotting, four clones exhibiting about a 10-fold 
increased level of expression of the 27 kDa isoform 
(4HL1-4) or the 25 kDa isoform (4Hs1-4) were selected 
(Figure 3A and Supplementary Figure S5A). The elevated 
expression of both eIF4H splice variants stimulated cell 
proliferation under low serum conditions (1% FCS) 
(Figure 3B and Supplementary Figure S5B) but also 
increased the number of cells in G2/M and reduced the 
percentage of cells in G1 phase (respectively 63% and 
67,8% versus 86,3% in control cells) (Figure 3C and 3D) 
and stimulated anchorage-independent cell growth based 
on cell colony formation in soft agar (Figure 3E and 
Supplementary Figure S5C).
We then evaluated the effect of eIF4H isoform 
overexpression on cell migration using both Boyden 
chamber or wound–healing assays. The number of 
migratory cells increased dramatically (more than 25 fold 
after 6 hours) in NIH3T3 cells expressing either eIF4H 
isoform (Figure 3F and Supplementary Figure S6A). We 
also observed that elevated levels of each eIF4H isoform 
in NIH3T3 cells stimulated wound closure compared 
to NIH3T3 control cells. Cells expressing the eIF4H 
isoforms were indeed able to migrate efficiently and cover 
more than 60% of the wounded area in 8 hours whereas 
control NIH3T3 cells were much less efficient in this 
process with less than 10% of the wounded area covered 
8 hours (Figure 3G and Supplementary Figure S6B).
In order to evaluate the invasive properties of these 
eIF4H–transfected clones, we studied their capacity to 
cross a reconstituted basement-membrane matrix in vitro, 
using invasion chambers. NIH3T3 control cells were poorly 
invasive, while expression of the eIF4H isoforms was 
associated with invasive properties (30-fold increase compared 
to control cells) (Figure 3H and Supplementary Figure S6C).
The role of each eIF4H isoform in chemosensitivity 
was next evaluated. Clones expressing eIF4H splice 
variants or control cells were treated with cisplatin or 
etoposide for 8 hours. The overexpression of both eIF4H 
isoforms inhibited caspase 3 and 7 activity compared to 
control cells (Figure 3I).
Finally, eIF4H-expressing NIH3T3 cells were 
subcutaneously grafted into athymic nude mice. 
eIF4H expression significantly enhanced the growth of 
transplanted subcutaneous tumors, as shown in Figure 3J.
Taken together, these data demonstrate that eIF4H 
overexpression protects against drug-induced apoptosis 
in vitro, but also promotes cell proliferation, migration, 
invasion, and tumor growth. Elevated levels of each 
isoform share the same outcome for these phenotypes.
eIF4H modulates the translation of specific 
mRNAs in vitro
Changes in the initiation of translation could signal 
either a change in global translational regulation or an 
altered translation of mRNAs encoding specific proteins. 
Usually, mRNAs encoding proteins whose expressions 
are highly regulated at the translational level have one or 
more structural elements within their 5′UTR that mediate 
translational control. Examples of such elements include 
Internal Ribosome Entry Sites (IRES), long or highly 
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Figure 3: Consequences of eIF4H overexpression in NIH3T3 cells. A. Expression analysis of eIF4H short isoforms (4Hs1 and 
4Hs2) and long isoforms (4HL1 and 4HL2) transfected into NIH3T3 stable clones. The control was provided by NIH3T3 cells stably 
transfected with the empty vector (3T3 EV). Loading was normalized to β-actin. B. Proliferation of NIH3T3 stable clones overexpressing 
short (4Hs1 and 4Hs2) or long (4HL1 and 4HL2) eIF4H isoforms under low serum conditions (1%) for 10 days. C. and D. Cell cycle 
analysis of NIH3T3 stable clones overexpressing short (4Hs) (C) or long (4HL) (D) eIF4H isoforms under low serum conditions was 
carried out using flow cytometry. E. Colony formation of eIF4H-transfected NIH3T3 cell lines in soft agar. The number of clones in agar 
was determined after 25 days. F. Cell migration quantification of NIH3T3 stable clones in a Boyden chamber assay after 6 hours. The 
number of migrating cells was calculated by integrating 12 independent cellular fields (from 3 independent assays). G. Cell migration 
after wound breakage of a monolayer of NIH3T3 stable clones was determined by a cell restitution assay. Migration was quantified as 
the percentage of surface recovery after 8 hours. H. Invasive properties of NIH3T3 stable clones using an invasion chamber assay. After 
24 hours incubation the invasive cell number was determined by crystal violet staining. Quantification of data was performed as in (E). 
I. Caspase 3/7 activity after 8 hours treatment with etoposide (20 μM) or cisplatin (50 μM) of control NIH3T3 cells or cells expressing the 
eIF4H isoforms. J. Tumorigenicity of NIH3T3 cells expressing the eIF4H isoforms. Tumor volumes were measured at the indicated time 
points after subcutaneous injection of NIH3T3 stable clones into 9 nude mice in each group. Error bars show SEM.
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structured 5′UTRs, and binding domains for specific 
regulatory proteins. Thus, we investigated the ability 
of eIF4H to modulate the cap-dependent translation of 
a luciferase reporter mRNA where either the AUG start 
codon is preceded by synthetic 5′UTRs with different 
lengths (from 57 to 327 nucleotides) (Figure 4A), or 
where the mRNA undergoes cap-independent translation 
driven by several viral and cellular IRESs, using luciferase 
bicistronic constructs (Figure 4D). We analyzed luciferase 
expression for each construct after transient transfection 
into NIH3T3 cells expressing each eIF4H isoform or in 
NIH3T3 control cells, as well as in A549 and HeLa cells 
where eIF4H was stably downregulated. Unambiguously, 
data show that constructs with longer 5′UTRs had 
increased activity in NIH3T3 eIF4H-expressing cells 
compared to control cells (Figure 4B). In agreement 
with these results, eIF4H depletion in A549 and HeLa 
cells led to the translation inhibition of reporters bearing 
longer 5′UTRs (over 188 nucleotides) (Figure 4C and 
Supplementary Figure S7B).
Interestingly, the overexpression of each eIF4H 
isoform stimulated cellular IRES activity by about 2-fold 
(constructs 7–11, Figure 4E). EMCV and FMDV viral IRES 
activity was increased to a lesser extent (constructs 12 and 
13, Figure 4E). As expected, the IRES activity of HCV, 
which was demonstrated to be eIF4A-independent [36], 
was not affected by increased eIF4H levels. The depletion 
of eIF4H in A549 cells also reduced cap-independent 
translation driven by FGF-2, VEGF-A, c-Myc, BIP, EMCV 
or FMDV IRES by about 40% (Figure 4F). Similar results 
were obtained with HeLa cells and eIF4H-knockout MEF 
cells (Supplementary Figure S7D and S7E). All these results 
demonstrate that eIF4H is able to specifically modulate 
the translation of both mRNA with long 5′UTRs and of 
IRES elements containing mRNAs. As observed earlier, 
the overexpression of both eIF4H isoforms share the same 
consequences on translational regulation.
eIF4H promotes the expression of potent growth 
and survival factors
These results led us to hypothesize that eIF4H could 
be involved in the translation of a limited set of cellular 
mRNAs with complex 5′UTRs encoding growth factors, 
cell cycle regulators, or anti-apoptotic effectors. If this was 
the case, aberrant expression of these mRNAs would result 
in cell growth defects and deregulation of the apoptotic 
machinery. The expression of cellular mRNAs with 
complex 5′UTRs, including cyclin D1, c-Myc, FGF-2, 
Bcl-xl and CIAP-1 was examined by western blotting in 
NIH3T3 cells overexpressing the eIF4H isoforms or in 
eIF4H-kd A549 and HeLa cells. Data clearly showed that 
overexpression of eIF4H in NIH3T3 cells significantly 
increased the levels of cyclin D1 and c-Myc, two oncogenes 
both implicated in the stimulation of cell proliferation 
and in apoptosis-regulated process, as well as cIAP1 
and Bcl-xL, two potent apoptosis inhibitors (Figure 5A). 
Interestingly, the two eIF4H isoforms elicited the same 
effect on the regulation of expression of these mRNAs. 
Conversely, the expression of cyclin D1, c-Myc, CIAP1 
and Bcl-xl declined in eIF4H-depleted A549 (Figure 5B) 
or HeLa cells (Supplementary Figure S7A). We next 
investigated the effect of eIF4H on the expression of two 
human mRNAs containing G-quadruplex structures in 
their 5′UTRs which encode potent growth factors, namely 
FGF-2 [37] and VEGF-A [38]. Western blot analysis 
demonstrated that eIF4H-kd in A549 cells (Figure 5B) 
as well as in HeLa cells (Supplementary Figure S8), 
lowered the expression of the 4 endogenous FGF-2 
isoforms. Finally, the VEGF protein levels in the culture 
medium were also decreased in eIF4H-kd A549 cells 
compared to control cells, as shown by ELISA (Figure 5C).
Taken together, these results suggest that eIF4H 
may contribute to tumor progression by promoting the 
expression of potent growth and survival factors.
eIF4H stimulates the translation of mRNAs 
containing complex 5′UTRs
To address whether eIF4H affected global translation 
or the translational efficiency of specific mRNAs we 
analysed polysome profiles from control versus eIF4H-kd 
A549 cells. Slight changes in the polysome profile (less 
polysomes and more free 40S and 60S subunits) were 
indicative of minor translation inhibition occurring in 
response to eIF4H knockdown (Figure 6A).
To examine the effects of changes in eIF4H levels 
on the translation of c-Myc, Bcl-xl, FGF-2 and cyclin D1 
mRNA in vivo, we determined the distribution of these 
mRNAs in sucrose density gradients. In control cells, Bcl-
xl mRNA sedimented predominantly with heavy polysomes 
whereas in eIF4H-silenced cells, it shifted to light 
polysomes, indicating a decrease in translation initiation of 
this mRNA (Figure 6B). Similar results were obtained with 
c-Myc, FGF-2 and cyclin D1 mRNAs. eIF4H depletion had 
a minimal effect on the polysomal distribution of actin and 
GAPDH mRNAs. These findings are in agreement with the 
observation that eIF4H depletion in A549 cells decreased 
c-Myc, FGF-2, Bcl-xl and cyclin D1 protein levels, while 
eIF4H overexpression in NIH3T3 cells resulted in increased 
expression of these proteins (Figure 5A and 5B).
In agreement with previous results obtained 
with reporter constructs, these data indicate that eIF4H 
preferentially stimulates the translation of mRNAs 
containing highly-structured 5′UTRs.
DISCUSSION
Lung cancer has been associated with a number of 
genetic and epigenetic alterations but remains the major 
cause of cancer-related deaths throughout the world [39]. 
Therapeutic options are still limited and the prognosis 
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remains poor even though the development of targeted 
therapies have improved lung cancer management. It has 
now become clear that genetic and epigenetic alterations 
are only the first layer of genetic reprogramming associated 
with tumor progression and that post-transcriptional 
regulation, including the control of mRNA translation, plays 
an important role in malignant transformation [40].
Protein synthesis is a major factor in determining cell 
phenotype and is a tightly regulated process that allows for a 
more rapid response than transcriptional control. Translation 
is primarily regulated at the ribosome recruitment step and 
the formation/activity of the eIF4F complex plays a central 
role in this mechanism. Tumor cells undoubtedly benefit 
from a hyperactive eIF4F complex, and this event is indeed 
observed in a wide range of cancers [41]. When activated, 
the eIF4F complex reprograms the cellular translational 
apparatus to amplify oncogenic signals and regulate 
neoplastic capabilities. The oncogenic activities of eIF4E 
have been demonstrated in multiple settings [42]. Similarly, 
eIF4G overexpression can drive the transformation of 
mouse cell lines [43], and eIF4A has been demonstrated 
to be an oncogene in T-cell acute lymphoblastic leukemia 
[24, 25]. Despite extensive interest in the eIF4E, eIF4G and 
eIF4A components, few studies have addressed the function 
of eIF4A cofactors, namely eIF4H and eIF4B, in cancer 
progression. Here we show that the two eIF4H isoforms are 
Figure 4: Effect of eIF4H on cap- and IRES-dependent translation. A. Schematic representation of monocistronic constructs with 
different 5′UTR lengths. B. Ratio of luminescence from the experimental reporter (Renilla) to the control reporter (Firefly; PGL3 from Promega) 
after co-transfection of NIH3T3 cells expressing the short (4Hs) or long (4HL) eIF4H isoforms, normalized to NIH3T3 empty vector control 
cells (set as 1). C. Ratio of luminescence from the experimental reporter (Renilla) to the control reporter (Firefly; PGL3 from Promega) after co-
transfection of A549 eIF4H knockdown cells (sh1 and sh2), normalized to the A549 scramble control cells (set as 1). D. Schematic representation 
of bicistronic constructs. IRESs cloned within the inter-cistronic region were either viral (EMCV, FMDV, HCV) or cellular (FGF-2, VEGF-A 
IRESA, VEGF-A IRESB, C-MYC and BIP). E. Ratio of luminescence from the IRES-dependent reporter (Firefly) to the cap-dependent reporter 
(Renilla) in NIH3T3 cells expressing the short (4Hs) or long (4HL) eIF4H isoforms, normalized to the NIH3T3 empty vector control cells (set as 1). 
F. Ratio of Firefly to Renilla luminescence in A549 eIF4H knockdown cells (sh1 and sh2), normalized to the A549 scramble control cells (set as 1).
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overexpressed in lung carcinomas and that the expression of 
this factor inversely correlates with the objective response 
to treatment.
We have demonstrated that each isoform of eIF4H acts 
as oncogene in NIH3T3 cells by increasing proliferation, 
migration and foci formation when grown on soft agar, and 
promoting chemoresistance. Moreover, eIF4H-expressing 
NIH3T3 cells are tumorigenic in nude mice. Our data also 
show that eIF4H stimulates the translation of mRNAs with 
either complex 5′UTRs or IRESs. A number of mRNAs 
enclosing these specific features encode growth factors, cell 
cycle or apoptotic machinery components. As a result, we 
have demonstrated that an alteration in eIF4H protein levels 
deeply affects the protein expression of potent cell growth 
and survival regulators or proteins involved in malignancy, 
such as cyclin D1, c-Myc, FGF-2, VEGF-A, Ciap1 and Bcl-
xl. These results could account for the strong effect of eIF4H 
overexpression on the resistance to drug-induced apoptosis 
and tumor progression.
These data are in agreement with the biochemical 
function of eIF4H that specifically stimulates the eIF4A 
helicase activity. It has been postulated that eIF4A helicase 
activity significant affects the translation of individual 
mRNAs. When eIF4A helicase activity is low, it is thought 
Figure 5: Effect of changes in eIF4H levels on the regulation of expression of genes involved in proliferation, apoptosis 
and cellular survival. Western blots were performed to compare the expression of proteins encoded by mRNAs harboring complex 
5′UTRs in both A. NIH3T3 control cells and clones stably-overexpressing eIF4H, and B. wild type A549 cells or A549 cells expressing 
scrambled (shScr) or eIF4H (sh1-4H, sh2-4H)-targeted shRNAs. The proteins detected as well as their molecular weights are indicated. The 
5′UTRs length of these mRNAs are 210 nucleotides for cyclin D1, 526 nucleotides for c-myc, 367 nucleotides for Bcl-xL, 1400 nucleotides 
for CIAP1, 1038 nucleotides for VEGF-A, and 484 nucleotides for FGF-2. C. Relative amount of VEGF–A secreted by A549 wild type 
cells or cells expressing scrambled (Scr) or eIF4H (sh1 and sh2)-targeting shRNAs, as determined by an ELISA assay.
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Figure 6: eIF4H stimulates the translation of mRNAs with structured 5′UTRs. A. Polysomal profiles of A549 cells transfected 
with eIF4H (sh1 and sh2) or control shRNAs (Scr). B. Distribution of endogenous mRNAs (encoding Bcl-Xl, c-Myc, FGF-2, cyclin D1, 
actin and GAPDH) in sucrose density gradients from control (Scr) and eIF4H (sh1 and sh2)-silenced cells. PCR products were analyzed by 
capillary micro-electrophoresis on the Shimadzu MultiNA system.
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that translation of mRNAs harboring short 5′UTRs is affected 
to a lesser degree than that of mRNAs possessing more 
extensive 5′UTR secondary structures. Indeed, dominant–
negative eIF4A mutant proteins inhibit the translation of 
mRNAs possessing 5′UTR secondary structures, while the 
translation of mRNAs with short 5′UTRs is unaffected by 
inhibition of the RNA helicase [44 , 45].
Recently it was shown that in breast cancer eIF4A 
preferentially stimulates translation of oncogenic genes, 
including cyclins, protein kinases, and mRNAs with G/C-
rich 5′UTRs with potential to form G-quadruplexes [46].
Furthermore eIF4H stimulate IRES activity. IRES 
elements have also been mostly reported in mRNAs 
containing long 5′UTRs with a high GC content and an 
extensive predicted secondary structure. Interestingly, data 
from Sun and collaborators indicated that eIF4H could be 
targeted internally to stem/loop structures, in combination 
with eIF4A [12]. This interaction, which induces rapid mRNA 
remodeling, could explain the stimulation of IRES activity 
by increasing the recruitment of the initiation complex, or 
IRES Trans Acting Factors (ITAFs). These data have been 
strengthened by other studies using eIF4A inhibitors. These 
molecules were shown to induce both cell cycle arrest of adult 
T-cell leukemia by decreasing cyclin D1 expression levels, 
and apoptosis by decreasing the expression levels of Bcl-xl 
and other anti-apoptotic factors [47, 48], but also to inhibit 
cancer cell proliferation, and suppress cap- or IRES-driven 
translation without affecting HCV IRES-mediated translation 
[49]. eIF4H-silencing experiments displayed identical results, 
consistent with published evidence demonstrating that eIF4H 
stimulates eIF4A activity [6–8, 12, 15].
One must note that eIF4A is a very weak helicase by 
itself but its activity is enhanced upon mutually-exclusive 
interactions with eIF4B or eIF4H [6–12]. It is well-
known that the mTOR signaling pathway results in the 
phosphorylation and activation of eIF4B by the ribosomal 
kinase S6K. Thus, nutrient starvation, osmotic stress, 
heat shock, ROS and DNA damage, which are known to 
decrease S6K activity, will cause the dephosphorylation of 
eIF4B and the inhibition of translation of highly-structured 
mRNAs [20, 21, 50, 51]. As previously mentioned, eIF4H is 
shorter than eIF4B but shares significant sequence homology 
in the RRM. However it lacks a large carboxy-terminal 
region encompassing the phosphorylation site (Ser422). We 
therefore envisage a model in which eIF4H is constitutively 
active and/or overexpressed leading to the expression of 
a subset of regulatory and stress response genes, while 
housekeeping genes remain unaffected. This hypothesis 
is supported by the fact that eIF4H knockdown inhibits 
the proliferation of A549 or HeLa cells under low serum 
culture conditions (Figure 2D and Supplementary Figure 
S3C). Moreover, eIF4H has been demonstrated to be under 
the transcriptional control of NF-kB [52], thought to be part 
of a stress response that is activated by a variety of stimuli 
including UV, serum starvation, and ER stress [53–55].
During tumor development and progression, hypoxia, 
acidosis, glucose depletion and a lack of other nutrients are 
caused by a combination of defective perfusion, abnormal 
tumor vasculature and uncontrolled proliferation of cancer 
cells, leading to eIF4B dephosphorylation [56]. Under these 
conditions, constitutively-active eIF4H could stimulate the 
translation of transcripts with complex 5′UTRs, conferring 
a relevant advantage to cancer cells for tumor growth, 
progression and resistance to chemotherapy. Nevertheless, 
it is clear that eIF4H has differential effects on the synthesis 
of proteins involved in the resistance to chemotherapy 
and lung tumor progression, and that these effects could 
represent a novel approach to lung carcinoma intervention.
eIF4H overexpression and its contribution to tumor 
growth are certainly not restricted to lung carcinoma. 
Indeed, eIF4H is detected in 93% of cancers (http://www 
.proteinatlas.org/ENSG00000106682/cancer), suggesting 
that eIF4H-mediated reprogramming of gene expression 
might be a general mechanism in tumoral development 
and a possible new therapeutic target.
MATERIALS AND METHODS
Human tissue samples
We prospectively recorded 12 patients with clinico-
pathological data (Table 1), who underwent surgery for 
lung carcinoma at Rangueil Hospital (Toulouse, France) 
from 2007 to 2008. Tissues samples (tumoral tissues and 
corresponding non-tumoral counterpart) were obtained 
from pulmonary lobectomy or pneumonectomy specimens 
during surgery and were immediately frozen in liquid 
nitrogen and stored at −80°C. The protocol had local ethical 
committee approval. Consents were obtained from patients 
before surgery. Tissue microarray consisting of 184 cases 
of SCLC was previously described [27]. All cases were 
diagnosed at Papworth Hospital (Cambridge, UK) between 
1998 and 2005. They were identified from hospital records 
and the formalin fixed, paraffin-embedded biopsy tissue 
samples were retrieved from the pathology department store 
along with their associated histology slides [27]. Clinical 
data were available for 53 of these patients that received 
etoposide and cisplatin doublet chemotherapy.
Protein extraction and western blotting
Frozen tissue samples were pulverized with “Mikro-
Dismembrator” (Sartorius, Aubagne, France) and resuspended 
in lysis buffer. Cells were scraped off into phosphate-
buffered saline and lysed. Western blotting was performed 
as previously described [28]. Membranes were probed with 
antibodies against eIF4H, eIF4B and eIF4A (Ab, 1:1000, Cell 
Signaling Technology, Danvers, MA), CIAP-1 (Ab, 1: 2000, 
R&D Systems, Mineapolis, MN), Cyclin D1 (mAb, 1:1000, 
Cell Signaling Technology, Danvers, MA), c-Myc (mAb, 1: 
500, Cell Signaling Technology, Danvers, MA), BCL-xL 
(mAb, 1:1000, Cell Signaling Technology, Danvers, MA), 
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FGF-2 (Ab, 1: 200, Santa Cruz Biothechnology, sc-79, Santa 
Cruz, CA) PABP (mAb, 1: 500, Santa Cruz Biothechnology, 
sc-32318, Santa Cruz, CA). Primary antibody incubation 
was followed by incubation with a horseradish peroxidase-
conjugated secondary antibody (anti-mouse dilution 1:5000, 
P8547, Sigma-Aldrich, Lyon, France or anti-rabbit dilution 
1:5000, P9795, Sigma-Aldrich, Lyon, France). Proteins were 
visualized using a chemiluminescence ECL kit (RevelBIOt 
Plus, Ozyme, Saint-Quentin-en-Yvelines, France). The signal 
was normalized using anti-β–actin (mAb dilution 1: 5000, 
AC-15, Sigma-Aldrich, France).
Immunohistochemical assay
The immunohistochemical analysis was performed 
with the same protocol for both TMA and human 
tissue samples. Slides were deparaffinised with xylene 
and rehydrated with ethanol. Antigenic retrieval was 
processed by submerging with the kit EnVision FLEX 
Target Retrieval Solution (Dako) on PT Link Dako. 
Between every step, a washing solution was used 
(EnVision FLEX Wash Buffer, Dako). Sections were then 
treated to block endogenous peroxidase activity and non-
specific sites with the kit EnVision FLEX Peroxidase-
Blocking Reagent (Dako, Denmark) during 5 min at room 
temperature.
The primary monoclonal anti-eIF4H antibody (anti-
rabbit, 1:1000, Cell Signaling Technology, Danvers, MA) 
was incubated for 20 min at room temperature followed 
by incubation with the labeled polymer (Envision Flex 
Horse Radish Peroxidase, Dako), for 20 min. Staining is 
completed by a 10 minute incubation at room temperature 
with 3,3′-diaminobenzidine (DAB)+ substrate-chromogen 
(EnVision FLEX Substrate Working Solution, Dako).
Table 1: Clinicopathologic characteristics of 12 patients with lung carcinoma
Patient Gender Surgical 
procedure
TNM Stage Histilogical 
type
Tumor 
size (cm)
Tumor 
extension
Positive lymph 
nodes
1 M
right 
pneumonectomy yT2N1 IIB adenocarcinoma 8 none intrapulmonary
2 M
right upper 
lobectomy pT2N2 IIIA
squamous cell 
carcinoma 3.5 none mediastinal
3 M
right lower 
lobectomy pT2N0 IB
squamous cell 
carcinoma 3.8 none none
4 M left upper lobectomy pT3 IIB
squamous cell 
carcinoma 6 pleura none
5 M left pneumonectomy pT2N1 IIB
squamous cell 
carcinoma 6 none intrapulmonary
6 M
left upper 
lobectomy pT2N0 IB
squamous cell 
carcinoma 4.5 none none
7 M
left 
pneumonectomy
pT1(LUL) 
pT2(LLL) 
N0
IA and IB
squamous cell 
carcinoma 
(LUL) + 
adenocarcinoma 
(LLL)
1.5 (LUL) 
/ 4 cm 
(LLL)
visceral 
pleura none
8 M
right upper 
lobectomy pT2N0 IB
Epidermoid 
carcinoma 3.5 none none
9 F left pneumonectomy pT2N2 IIIA adenocarcinoma 9
visceral 
pleura mediastinal
10 M
left 
pneumonectomy pT3N0 IIB
squamous cell 
carcinoma 5
mediastinal 
pleura none
11 M
right lower 
lobectomy pT2N0 IB adenocarcinoma 4.8 none none
12 F right upper lobectomy pT2N0 IB adenocarcinoma 7 none none
For each patient, numbered from 1 to 12, the relevant clinicopathologic characteristics, including their sex, surgical procedure, 
TNM classification, stage, histological type, size and extension of the primary tumors, and the presence of positive lymph 
nodes are shown. LUL (Left Upper Lobe) and LLL (Left Lower Lobe).
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All slides were counterstained with hematoxylin to 
visualize the nuclei (EnVision FLEX Hematoxylin) during 
5 min room temperature.
Scoring was performed blinded to the clinical data 
relating to the case, simultaneously by two observers. 
The staining was homogeneous in tumoral cells. As we 
observed a good correlation between the percentage of 
positive tumoral cells and intensify, we scored in 2 groups: 
negative or positive for the expression of eIF4H.
Cell culture
The HeLa (obtained from ATCC n°. CCL2TM), 
A549 (ATCC n° CCL-185) and NIH 3T3 (obtained from 
European Collection of Cell Cultures N° 93061524) cell 
lines were maintained in DMEM 1g/l glucose supplemented 
with 10% FCS, 1% glutamine, 0.1% gentamycin and 
incubated in a humidified atmosphere of 5% CO
2
 at 37°C.
Establishment of NIH3T3, A549 and HeLa 
cellular models
Stable transfected NIH3T3 clones were obtained by 
JetPEI (Polyplus) transfection with two eIF4H-expressing 
vectors (see below). Cultures were maintained for 2 weeks 
in the presence of 1 mg/ml G418, then 36 clones from 
each transfection experiment were picked and transferred 
onto 24-well plates before cultivation in larger dishes and 
eIF4H expression analysis.
Lentiviral constructs targeting eIF4H (TRCN 
0000153576, corresponding to the sequence CCGGGA 
TCTCAGCATAAGGAGTGTACTCGAGTACACTCCTT 
ATGCTGAGATCTTTTTTG –sh4H1; and TRCN0000 
275667, corresponding to the sequence CCGGGATCTCA 
GCATAAGGAGTGTACTCGAGTACACTCCTTATGCTG 
AGATCTTTTTG - sh4H2) and non-targeting shRNA 
vectors (SHC002V, shScr) were purchased from Sigma. After 
transduction, A549 and HeLa cells were selected using 1 μg/
ml puromycin.
Plasmid constructions
The sequences encoding the two splice variants of 
eIF4H were PCR amplified using the primer pair 4HATG-F 
(AAGCTAGCTATCCATGGCGGACTTCGACACCTACG 
ACG) and 4HSTOP-R (AAAAGATCTCCCGGGA GCTC 
TCATTCTTGCTC CTTTTGAACGAC), with cDNA from 
HeLa cells as template. PCR products were digested by 
NheI and BglII and inserted into pCEN [29] digested 
by SpeI and BamHI in order to create pC4HsEN and 
pC4HLEN plasmids encoding respectively the short and 
the long eIF4H isoforms upstream of an EMCV-NEO 
cassette. Constructs were confirmed by sequencing and 
used to stably transfect NIH3T3 cells. Reporter vectors 
with long 5′UTRs were derived from a modified pRL-CMV 
(Promega) presenting a HA tag at the 5′ end of the luciferase 
coding region [30]. To generate PRL27, a deletion was 
performed between the NheI and HindIII sites using the 
Quikchange XL site-directed mutagenesis kit (Stratagene) 
and the oligonucleotides DEL1-F (5′GTTTAGTGAACCGT 
CAGATCACTAGAAGCTTGCTAGCCACCATGGCTT 
ACCCCG 3′) and DEL1-R (5′GGGTAAGCCATGGT 
GGCTAGCAA GCTTCTAGTGATCTGACGGTT CACT 
AAAC3′). Oligonucleotide Del1-F introduces a NcoI site 
at the luciferase AUG initiation codon. NcoI and HindIII 
digestion of pRL27 and double strand oligonucleotide 
insertion generated reporter constructs harboring a variable 
5′UTR from nucleotides 57 to 327. The 17 nucleotides 
region upstream of the luciferase AUG start codon remained 
unchanged in all vectors. The resulting plasmids, namely 
pRL57, pRL115, pRL188, pRL217, pRL265 and pRL327, 
were checked by DNA sequencing. The sequences, folding 
and free energy of the thermodynamic prediction of the 
variable 5′UTRs are provided in Supplementary Figure S1. 
The bicistronic vectors used in this study have been 
previously described and validated [31 , 32].
Plasmid transfection
A549, HeLa or NIH3T3 cells were seeded into 
24-well dishes 1 day prior to transfection and allowed to 
grow to 50% confluence. According to the manufacturer’s 
instructions, 250 ng of each monocistronic or bicistronic 
reporter plasmid was transfected into the cells with the 
JetPEI reagent (Polyplus Transfection Illkirch, France) 
in 150 mM NaCl. Either the pRL-CMV control vector 
expressing Renilla luciferase, or the pGL3 firefly 
luciferase reporter vector (50 ng) were co-transfected into 
cells. This second reporter gene allowed the expression to 
be normalized for calculation of transfection efficiency.
Migration assay
Cell migration was measured using the Boyden 
chamber assay (8 μm pore size transwells, Corning, Cell 
Biolabs, CBA-100-C, San Diego, CA). Cells (2.5x104) 
in 0.5% FCS DMEM were seeded in the upper well. The 
lower chamber was filled with 10% FCS media. After 6 or 
24 h, the non-migratory cells on the upper surface were 
removed with a cotton swab, and cells that had migrated 
to the lower filter were fixed and stained with 0.5% crystal 
violet. Migratory cells were counted under the light 
microscope. Each assay was performed in duplicate and 
three independent experiments were performed.
Invasion assay
Invasion assay was assessed using 8 μm membrane 
pores coated with Matrigel Matrix (BD BioCoat Matrigel 
Invasion Chamber, BD biosciences, Franklin Lakes, NJ 
USA). 5x104 NIH3T3, A549 or HeLa cells were suspended in 
10% FCS DMEM, placed in the upper chamber and cultured 
for 24 h at 37°C. The cells that had invaded to the lower 
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surface of the filter inserts were stained with crystal violet 
prior to cell density evaluation. Each assay was performed in 
duplicate and three independent experiments were carried out.
Anchorage-independent growth assay
5 × 104 NIH3T3 cells resuspended in DMEM 
containing 0.33% Noble agar (Gibco) were seeded onto 
6 cm dishes over a 0.5% Noble agar lower coat [33]. 
Cells were fed every 3 days and colony number was 
scored after 25 days by 3-(4.5-dimethylthiazol-2-yl)-2.5-
diphenyltetrazolium bromide (MTT) staining.
Proliferation assays
Control NIH3T3 cells and stable clones overexpressing 
either the short eIF4H isoform (4Hs1 and 4Hs2) or the long 
isoform (4HL1 and 4HL2) were seeded in 96-well plates (800 
cells) and cultivated under low serum conditions (1% FCS) 
for 10 days. HeLa or A549 cells were seeded in 96-well plates 
(1000 cells) and cultivated in low serum medium (0.5% FCS) 
for 5 days. Viable cell number was determined on the basis of 
mitochondrial conversion of MTT to formazine. Cells were 
incubated with MTT for 2 h at 37°C and the crystals were 
solubilized in dimethyl sulfoxide for 1 hour at RT. Optical 
density was read at 560 nm (Asys, Serlabo Technologies, 
Entraigues sur la Sorgue, France).
Wound healing assay
Migration (wound healing) was performed using 
the CytoSelect™ 24-Well Wound Healing Assay (Cell 
Biolabs, San Diego, CA), according to the manufacturer’s 
instructions. Briefly, NIH3T3 cells (2.5 × 105) were seeded 
in wells with inserts and cultured until a monolayer 
was formed (24 h). After insert removal, migration was 
monitored for 3, 8 or 20 h. All experiments were repeated 
at least three times and data are presented as mean values.
Cell cycle analysis
Cells were washed with phosphate-buffered saline and 
fixed in cold 70% ethanol overnight at −20°C. Cells were 
then washed twice with phosphate-buffered saline −0.1% 
bovine serum albumin and once with phosphate-buffered 
saline then labeled using propidium iodide staining for 30 
min (Invitrogen). Cell cycle distribution was evaluated by 
fluorescence analysis on a MACSQuant VYB (Miltenyi 
Biotec). Cell doublets were excluded and 10000 events per 
condition were analyzed.
Quantification of VEGF by ELISA
The amount of VEGF in the A549 cell culture 
medium was measured using ELISA kits specific for 
VEGF (R&D Systems, Minneapolis, MN, USA), 
according to the manufacturer’s instructions.
Drug treatments / Apoptosis assay
To test the effect of different drugs, cells were 
plated into 96-well plates and incubated with varying 
concentrations of drugs for 8 h. NIH3T3 and A549 stable 
clones were treated with a range of 10 to 100 μM for cisplatin 
and 5 to 50 μM for etoposide . HeLa cells were incubated 
in the presence of 100 μM cisplatin, 20 μM etoposide. 
Apoptosis was evaluated by measuring caspase-3/7 activity 
using the Caspase-Glo 3/7 Assay (Promega, Lyon, France). 
An incubation of 1 h at 37°C was performed after addition 
of the Caspase-Glo 3/7 reagent. Luminescence was recorded 
using the Centro LB 960 (Berthold Technologies, Bad 
Wilbad, Germany) and the background luminescence was 
subtracted from experimental values.
Luciferase activity
The two luciferase activities (LucR and LucF) 
were measured in NIH3T3, A549 or HeLa cell extracts 
using the Dual Luciferase kit (Promega, Lyon, France) as 
previously described [34].
Sucrose-gradient fractionation, polysome-
associated RNAanalysis and RT–PCR
Sucrose density-gradient centrifugation, used to 
separate ribosomes into polysomal and subpolysomal 
forms, were performed essentially as described previously 
[35]. Briefly, extracts from A549 cells were prepared by 
lysis at 4°C in extraction buffer (10 mM Tris–HCl, pH 8.0, 
140 mM NaCl, 1.5 mM MgCl2, 0.5% Nonidet-P40 and 500 
U/ml RNAsin), and nuclei were removed by centrifugation 
(12 000g, 10 s, 4°C). The supernatant was supplemented 
with 20 mM dithiothreitol, 150 μg/ml cycloheximide, 1 mM 
phenylmethylsulfonyl fluoride and centrifuged (12 000g, 5 
min, 48°C). The supernatant was layered onto a 12 ml linear 
sucrose gradient (15–40% sucrose (w/v) supplemented 
with 10 mM Tris–HCl, pH 7.5, 140 mM NaCl, 1.5 mM 
MgCl2, 10 mM dithiothreitol, 100 μg/ml cycloheximide) 
and centrifuged in a SW41Ti rotor (Beckman, Villepinte, 
France) for 2 h at 160 000g, 4°C, without braking. Fractions 
of 750 μl were collected using an ISCO collector and UV 
optical unit type 11 (Lincoln, NE). The data were acquired 
using an analog-to-digital converter USB-1208 device and 
Tracer-DAQ software (Measurement Computing Inc.). 
Each fraction was digested with 100 μg of proteinase K in 
1% SDS and 10 mM EDTA (30 min, 37°C). RNAs were 
then recovered by phenol–chloroform–isoamyl alcohol 
extraction followed by ethanol precipitation. Pellets were 
washed with 70% ethanol pre-stored at 20°C, air-dried and 
resuspended in appropriate volumes of RNAse-free water. 
RNAs were analyzed by electrophoresis on 1.2% agarose 
gels. Reverse transcription was performed on 1/10 of each 
fraction using the RevertAid First Strand cDNA Synthesis 
Kit (Fermentas) with a random hexamer according to the 
manufacturer’s recommendations. The resulting cDNA 
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fragments were PCR-amplified using the Phusion Taq DNA 
polymerase (Finnzymes) and specific primers.
Tumor growth
Animal experiments were conducted in accordance 
with the European directive, and with approval from the 
Regional Ethics Committee of Midi-Pyrénées for Animal 
Experimentation. NIH3T3 (2 × 106), A549 or HeLa cells 
(1 × 106) were injected subcutaneously into the flank of 
6-week-old female nude mice (Janvier, Le Genest-Saint-
Isle, France). Animal body weight and tumor volumes were 
measured 3 times per week until the end of the experiment.
Statistical analyses
All experimental data are expressed as mean ± SEM 
and were analyzed by ANOVA followed by Student’s 
t-test. Differences were considered significant at values of 
P < 0.05 (* : P < 0.05; ** : P < 0.01; *** : P < 0.001). 
For clinical data, categorical variables were summarized 
as the frequency and percentage, Comparison between 
groups were performed using chi-square test or fisher 
exact test for qualitative variable.
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